Choreo LLC Buys New Shares in Supernus Pharmaceuticals, Inc. $SUPN

Choreo LLC bought a new stake in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) in the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund bought 11,457 shares of the specialty pharmaceutical company’s stock, valued at approximately $572,000.

Several other institutional investors also recently bought and sold shares of SUPN. Hantz Financial Services Inc. grew its stake in Supernus Pharmaceuticals by 81.7% during the third quarter. Hantz Financial Services Inc. now owns 625 shares of the specialty pharmaceutical company’s stock worth $30,000 after buying an additional 281 shares during the period. USA Financial Formulas purchased a new stake in Supernus Pharmaceuticals during the third quarter worth approximately $50,000. EverSource Wealth Advisors LLC purchased a new stake in Supernus Pharmaceuticals during the second quarter worth approximately $51,000. Smartleaf Asset Management LLC grew its stake in Supernus Pharmaceuticals by 30.8% during the third quarter. Smartleaf Asset Management LLC now owns 1,137 shares of the specialty pharmaceutical company’s stock worth $54,000 after buying an additional 268 shares during the period. Finally, Raymond James Financial Inc. purchased a new stake in Supernus Pharmaceuticals during the second quarter worth approximately $55,000.

Analyst Upgrades and Downgrades

Several research firms have issued reports on SUPN. Weiss Ratings reiterated a “sell (d+)” rating on shares of Supernus Pharmaceuticals in a research note on Friday, March 27th. Wall Street Zen cut shares of Supernus Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research report on Sunday, March 8th. Zacks Research cut shares of Supernus Pharmaceuticals from a “hold” rating to a “strong sell” rating in a research report on Thursday, January 29th. Finally, Craig Hallum set a $65.00 target price on shares of Supernus Pharmaceuticals in a research report on Wednesday, February 25th. Four analysts have rated the stock with a Buy rating, one has issued a Hold rating and two have issued a Sell rating to the company’s stock. According to MarketBeat.com, the company has an average rating of “Hold” and a consensus target price of $62.17.

Insider Activity at Supernus Pharmaceuticals

In other Supernus Pharmaceuticals news, VP Padmanabh P. Bhatt sold 7,250 shares of the stock in a transaction on Wednesday, March 18th. The shares were sold at an average price of $49.60, for a total transaction of $359,600.00. Following the sale, the vice president directly owned 17,044 shares of the company’s stock, valued at approximately $845,382.40. This represents a 29.84% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Bethany Sensenig sold 4,475 shares of the stock in a transaction on Thursday, February 19th. The stock was sold at an average price of $51.01, for a total transaction of $228,269.75. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 120,881 shares of company stock valued at $6,139,356 in the last ninety days. 8.80% of the stock is owned by insiders.

Supernus Pharmaceuticals Trading Up 4.4%

NASDAQ SUPN opened at $51.39 on Friday. The company’s fifty day simple moving average is $51.40 and its 200-day simple moving average is $49.83. Supernus Pharmaceuticals, Inc. has a 52 week low of $29.16 and a 52 week high of $59.68. The stock has a market cap of $2.96 billion, a P/E ratio of -75.57, a PEG ratio of 1.53 and a beta of 0.73.

Supernus Pharmaceuticals Profile

Supernus Pharmaceuticals, Inc, headquartered in Rockville, Maryland, is a specialty pharmaceutical company dedicated to developing and commercializing central nervous system (CNS) therapies. Since its founding in 2003, Supernus has focused on advancing treatments for neurological disorders, with an emphasis on improving patient quality of life through innovative dosage forms and sustained‐release formulations.

The company’s marketed portfolio includes Trokendi XR and Oxtellar XR, extended‐release antiepileptic medications designed to maintain stable drug levels for seizure control, as well as Qelbree (viloxazine extended‐release capsules), approved for the treatment of attention‐deficit/hyperactivity disorder (ADHD) in pediatric and adult patients.